What is PostEra?
Founded in 2019 and headquartered in Massachusetts, PostEra provides medicinal chemistry as a service, utilizing proprietary machine learning algorithms to streamline the drug discovery process. The company addresses the inherent complexities of pharmaceutical research by automating chemical synthesis and optimization, thereby reducing the time and cost associated with bringing new therapeutics to market. Its market position is defined by its ability to bridge the gap between computational biology and traditional laboratory experimentation, serving as a vital partner for organizations seeking to optimize their R&D pipelines through data-driven insights.
How much funding has PostEra raised?
PostEra has raised a total of $92M across 2 funding rounds:
Series A
$24M
Corporate Investment
$68M
Series A (2022): $24M with participation from ACE, Metaplanets, I2BF Global Ventures, HOF Capital, Lifeforce Capital Gp I, The Pioneer Fund, The Clermont Group, R. Martin Chavez, and Breyer Capital
Corporate Investment (2022): $68M led by National Institutes of Health
Key Investors in PostEra
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical support for scientific innovation.
ACE
ACE is a multi-stage private equity and venture capital group that provides operational and strategic support to disruptive innovators across global markets.
Breyer Capital
Breyer Capital is an independent global venture capital firm focused on long-term, idea-driven investments in artificial intelligence and machine learning.
What's next for PostEra?
With the recent infusion of capital, PostEra is well-positioned to scale its technological infrastructure and expand its collaborative research initiatives. The strategic focus will likely center on enhancing the predictive accuracy of its machine learning models and broadening its therapeutic reach across diverse disease areas. As the company matures, it is expected to deepen its integration within the global pharmaceutical supply chain, potentially establishing new benchmarks for speed and precision in medicinal chemistry. The ongoing support from its diverse investor base provides the necessary runway to navigate the high-stakes environment of drug development while maintaining a competitive edge in the rapidly evolving AI-biotech sector.
See full PostEra company page
